Lyon
France
27
2026-04-16
10
2026-03-10
These are the the leading inventors for applications assigned to Centre Leon Berard:
Centre Leon Berard based in Lyon, FR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
METHOD FOR PRODUCING ONE OR SEVERAL SHARED CANCER EPITOPE(S) DERIVED FROM ALTERNATIVE TRANSLATIONAL CONTROL
#2 | 2026-02-26LIPOSOMAL FORMULATION AND USE IN A COMBINATION PRODUCT AS AN ANTI-TUMOUR THERAPY
#3 | 2025-07-24Benzimidazole derivatives for use in the treatment or prevention of a histiocytosis or a craniopharyngioma
#4 | 2025-07-24XOPHOS INHIBITORS FOR USE IN THE TREATMENT OF B-CELL LYMPHOMA
#5 | 2025-05-08NEW METHOD FOR IDENTIFYING HERV-DERIVED EPITOPES
#6 | 2025-01-16TRANSCRIPTOMIC SIGNATURE BASED ON HERVs EXPRESSION TO CHARACTERIZE LEUKEMIC STEM CELLS AND USEFUL AS A LSC MARKER
#7 | 2025-01-09USE OF A TRANSCRIPTOMIC SIGNATURE BASED ON HERVs EXPRESSION TO CHARACTERIZE NEW ACUTE MYELOID LEUKEMIA SUBTYPES
#8 | 2024-09-05STABLE CLONAL CELL LINE AS A HBV RNA STANDARD
#9 | 2023-09-07 ✅ Patent 12,570,632 granted on 2026-03-10INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER
#10 | 2022-12-08FLUORESCENT PROBE AND APPLICATIONS THEREOF
#11 | 2022-11-03 ✅ Patent 12,509,465 granted on 2025-12-30Benzoimidazole Derivatives As Anticancer Agents
#12 | 2021-10-07 ✅ Patent 11,801,400 granted on 2023-10-31Therapy apparatus for treating tissue by the emission of remote crossed focused ultrasound waves
#13 | 2021-09-23 ✅ Patent 11,384,081 granted on 2022-07-12Benzoimidazole derivatives as anticancer agents
#14 | 2021-06-17 ✅ Patent 12,433,838 granted on 2025-10-07LIPOSOMAL FORMULATION OF BACTERIAL LIPOPOLYSACCHARIDE COMBINED WITH A CYTOTOXIC AGENT, AND USE THEREOF IN ANTI-TUMOUR THERAPY
#15 | 2019-01-31Inhibitors of the Interaction BCL-2 L10 / IP3 Receptors
#16 | 2018-10-11 ✅ Patent 11,203,641 granted on 2021-12-21Screening for anti-cancer compounds using netrin-1 activity
#17 | 2018-08-23PREDICTIVE METHOD FOR CHARACTERIZING THE SENSITIVITY OF A TUMOUR IN RESPONSE TO A DNA-BREAKING TREATMENT
#18 | 2017-01-12 ✅ Patent 10,197,578 granted on 2019-02-05Predictive method of characterizing the radiosensitivity and tissular reaction of a patient to therapeutic ionizing radiation
#19 | 2016-12-22METHOD FOR PRODUCING INDUCED PLURIPOTENT CELLS
#20 | 2015-09-10LKB1 AS PREDICTIVE MARKER OF EVEROLIMUS EFFICACY IN BREAST CANCER
#21 | 2014-11-06 ✅ Patent 9,683,986 granted on 2017-06-20Treatment of cancer by inhibition of the MYD88/ERK MAP kinase interaction
#22 | 2014-07-03INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMA
#23 | 2013-04-04ASSESSMENT OF CANCER RISK BASED ON RNU2 CNV AND INTERPLAY BETWEEN RNU2 CNV AND BRCA1
#24 | 2012-08-30Determination of 17q Gain in Neuroblastoma Patients by Analysis of Circulating DNA
#25 | 2012-05-03 ✅ Patent 8,709,719 granted on 2014-04-29ZNF217 a new prognostic and predictive biomarker of recurrent invasive and metastatic phenotypes in breast cancer
#26 | 2011-09-22INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMA
#27 | 2005-07-21 ✅ Patent 7,414,024 granted on 2008-08-19Proteins with IL-6 inhibiting activity
Also check out CENTRE LEON BERARD's (LYON, France) applicant profile with 24 patent applications submitted.
16820 ⎘